Recursion appoints Robert Hershberg as new board chair; Martin Chavez to exit at 2024 annual meeting

RECURSION PHARMACEUTICALS, INC.

Martin Chavez not standing for re-election; term ends at 2024 Annual Meeting; no disagreement with company.
Board elects Robert Hershberg as new Chair effective at 2024 Annual Meeting; board size reduced from 9 to 8.
Hershberg, board member since May 2020, is CEO of HilleVax and former Celgene executive with 25+ years experience.
Auditor changed to PricewaterhouseCoopers for FY 2024 engagement, as previously disclosed on May 9, 2024.

item 4.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Robert Hershberg

Chair of the Board

RXRX · RECURSION PHARMACEUTICALS, INC.

Filed: May 24, 2024, 7:59 PM ET

the Board elected Robert Hershberg, M.D., Ph.D. as the Chair of the Board, effective at the 2024 Annual Meeting

Departed

R. Martin Chavez

Chair of the Board

RXRX · RECURSION PHARMACEUTICALS, INC.

Successor: Robert Hershberg
Filed: May 24, 2024, 7:59 PM ET

R. Martin Chavez, Ph.D., Chair of the Board and member of the Audit Committee of the Board, informed the Company that he will no longer stand for re-election to the Board as a Class III Director at the 2024 Annual Meeting of Stockholders

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Hershberg changed role as Chair of the Board at RECURSION PHARMACEUTICALS, INC..

Action: elected as
Role: Chair of the Board

Exact text from the filing

the Board elected Robert Hershberg, M.D., Ph.D. as the Chair of the Board, effective at the 2024 Annual Meeting

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

R. Martin Chavez departed as Chair of the Board at RECURSION PHARMACEUTICALS, INC..

Action: will no longer stand for re-election
Role: Chair of the Board

Exact text from the filing

R. Martin Chavez, Ph.D., Chair of the Board and member of the Audit Committee of the Board, informed the Company that he will no longer stand for re-election to the Board as a Class III Director at the 2024 Annual Meeting of Stockholders

View on SEC.gov

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-24-000065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.